Gilles Gallant

1.1k total citations · 1 hit paper
19 papers, 819 citations indexed

About

Gilles Gallant is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gilles Gallant has authored 19 papers receiving a total of 819 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Gilles Gallant's work include Lung Cancer Treatments and Mutations (6 papers), Cancer therapeutics and mechanisms (3 papers) and HER2/EGFR in Cancer Research (3 papers). Gilles Gallant is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer therapeutics and mechanisms (3 papers) and HER2/EGFR in Cancer Research (3 papers). Gilles Gallant collaborates with scholars based in United States, Canada and United Kingdom. Gilles Gallant's co-authors include Jerry L. Klein, Wendy Halpern, Trisha M. Wise‐Draper, Toshihiko Doi, Kaku Saito, Yun Oh, Hiroji Iwata, Ian E. Krop, Shunji Takahashi and Larry Lo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Gilles Gallant

18 papers receiving 794 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

2020 248 citations Junji Tsurutani, Hiroji Iwata et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Gilles Gallant

Since Specialization

Citations

This map shows the geographic impact of Gilles Gallant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gilles Gallant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gilles Gallant more than expected).

Fields of papers citing papers by Gilles Gallant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gilles Gallant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gilles Gallant. The network helps show where Gilles Gallant may publish in the future.

Co-authorship network of co-authors of Gilles Gallant

This figure shows the co-authorship network connecting the top 25 collaborators of Gilles Gallant. A scholar is included among the top collaborators of Gilles Gallant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gilles Gallant. Gilles Gallant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study. 2025 ·Journal of Clinical Oncology ·Rebecca S. Heist, Elaine Shum, Esther García Pagès, Malinda Itchins, (unknown), (unknown), George R. Blumenschein, Sarah Benafif, Mariam P. Alexander, Rohit Joshi, Jih‐Hsiang Lee, Nicholas Coupe, (unknown), Brian Fiske, (unknown), (unknown), Thao Phuong Nguyen, Tinghui Wu, Gilles Gallant, Chang Gon Kim	1
2	MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study. 2024 ·Journal of Clinical Oncology ·Melissa L. Johnson, Timothy F. Burns, Jonathan R. Thompson, Alexander I. Spira, Mariam P. Alexander, George R. Blumenschein, Joel Michalski, Sanela Bilic, (unknown), Katharine C. Lai, (unknown), (unknown), (unknown), Tinghui Wu, Gilles Gallant, Rebecca S. Heist	2
3	Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer. 2023 ·Journal of Clinical Oncology ·Alexander I. Spira, Melissa L. Johnson, George R. Blumenschein, Timothy F. Burns, Jonathan R. Thompson, Amit Deshpande, William C. Comb, Brian Fiske, Gilles Gallant, Rebecca S. Heist	2
4	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors breakdown → 2020 ·Cancer Discovery ·Junji Tsurutani, Hiroji Iwata, Ian E. Krop, Pasi A. Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles H. Redfern, Kenji Tamura, Trisha M. Wise‐Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T. Li	248
5	Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. 2014 ·Journal of Clinical Oncology ·Zev A. Wainberg, Saeed Rafii, Ramesh K. Ramanathan, Lida A. Mina, Lauren A. Byers, Rashmi Chugh, Jonathan W. Goldman, Jasgit C. Sachdev, Daniela Matei, Jennifer J. Wheler, Joshua W. Henshaw, Charlie Zhang, Gilles Gallant, Johann S. de Bono	28
6	Are the Large Pharmaceutical and Biotechnology Companies Driving the Discovery, Research and Development of Targeted Cancer Therapies? 2011 ·Future Medicinal Chemistry ·Gilles Gallant	1
7	A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM) 2010 ·Blood ·Andrew R. Belch, Atul Sharma, Andrew Spencer, Stefano Tarantolo, Nizar J. Bahlis, Dinesh Doval, Gilles Gallant, (unknown), Jerry L. Klein, Asher Chanan‐Khan	19
8	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy 2009 ·Expert Opinion on Biological Therapy ·Norma Lynn Fox, Robin Humphreys, Troy A. Luster, Jerry L. Klein, Gilles Gallant	50
9	Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer 2008 ·Lung Cancer ·F. Anthony Greco, Philip Bonomi, Jeffrey Crawford, Karen Kelly, Yun Oh, Wendy Halpern, Larry Lo, Gilles Gallant, Jerry L. Klein	142
10	Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice 2004 ·Cancer Immunology Immunotherapy ·Robert J. Melder, Blaire L. Osborn, Todd Riccobene, Palanisamy Kanakaraj, Ping Wei, Guoxian Chen, David T. Stolow, Wendy Halpern, Thi‐Sau Migone, Qi Wang, Krzysztof Grzegorzewski, Gilles Gallant	92
11	Tumor Targeting, Dosimetry and Clinical Response Data for Lymphorad-131 (LR131; Iodine I-131 Labeled B-Lymphocyte Stimulator) in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma. 2004 ·Blood ·Andrew R. Belch, Alexander McEwan, Joanne Hewitt, (unknown), Michael G. Stabin, A.B. Brill, Gilles Gallant, (unknown), Jerry L. Klein	6
12	Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. 2003 ·PubMed ·Weijing Sun, James Stevenson, (unknown), David J. Vaughn, (unknown), Daniel G. Haller, Marvin B. Cohen, Justin Kopit, Gilles Gallant, Peter J. O’Dwyer	9
13	Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. 2002 ·PubMed ·Ruth Plummer, Michele Ghielmini, Paula Calvert, Maurizio Voi, J. Renard, Gilles Gallant, Elora Gupta, Hilary Calvert, Cristiana Sessa	21
14	Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer 2000 ·Journal of Clinical Oncology ·U. Gatzemeier, Joachim von Pawel, Maya Gottfried, G.P.M. ten Velde, K. Mattson, (unknown), Peter Harper, Franco Salvati, G. Robinet, A. Lucenti, Jan Bogaerts, Gilles Gallant	177
15	Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin 1998 ·Cancer ·Eric J. Bow, Gilles Gallant, G. J. Williams, (unknown), Tsiporah B. Shore, Morel Rubinger, Brent Schacter	6
16	Synthesis and anti-HIV activity of new urea and nitrosourea derivatives of diamino acids 1995 ·Bioorganic & Medicinal Chemistry ·Hélène Dulude, (unknown), Gilles Gallant	8
17	Synthesis and in vitro anti-HIV and antitumor activity of new 2-chloroethyl thiocarbamates 1995 ·Bioorganic & Medicinal Chemistry Letters ·Gilles Gallant, (unknown), Hélène Dulude	3
18	Synthesis, chemical half-life and decomposition of new N3-(substituted) derivatives of CCNU 1994 ·Bioorganic & Medicinal Chemistry Letters ·Gilles Gallant, (unknown), Hélène Dulude	3
19	Chemical stability of new urea and nitrosourea derivatives of diamino acids. 1994 ·Bioorganic & Medicinal Chemistry Letters ·Hélène Dulude, (unknown), Gilles Gallant	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact